Pu et al. (2024) conducted a meta-analysis concerning adverse events associated with CDK4/6 inhibitors in the treatment of HR+/HER2-advanced breast cancer, conclusively demonstrating a significant increase in adverse events related to constipation attributable to CDK4/6 inhibition. This evidence concerns the gene ERBB2 and breast cancer.